Results 141 to 150 of about 5,288 (183)

Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. [PDF]

Aging (Albany NY), 2021
Wang X, Fei Y, Liu X, Zhang T, Li W, Jia X, Liu X, Qiu L, Qian Z, Zhou S, Ren X, Zhai Q, Meng B, Li L, Zhang H.   +14 more
europepmc   +1 more source

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. [PDF]

Cancer Chemother Pharmacol, 2020
Mu S, Tang Z, Novotny W, Tawashi M, Li TK, Ou Y, Sahasranaman S.   +6 more
europepmc   +1 more source

Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling. [PDF]

Clin Transl Sci, 2022
Huth F, Schiller H, Jin Y, Poller B, Schuhler C, Weis W, Woessner R, Drollmann A, End P.   +8 more
europepmc   +1 more source

The BMX Tyrosine Kinase : A Signal Mediator in Hematopoietic and Endothelial/Epithelial Cells [PDF]

, 2003
Ekman, Niklas
core  

Correction: Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. [PDF]

J Exp Clin Cancer Res
Wang J, Liu X, Hong Y, Wang S, Chen P, Gu A, Guo X, Zhao P.   +7 more
europepmc   +1 more source

Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents. [PDF]

Front Cell Dev Biol, 2021
Wu CP, Murakami M, Wu YS, Chi YC, Hsiao SH, Huang YH, Hung TH, Ambudkar SV.   +7 more
europepmc   +1 more source

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]

Cancer Immunol Immunother
Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, Siddiqui A, Pracha SH, Roth P, Iwenofu OH, Oghumu S.   +10 more
europepmc   +1 more source

Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada. [PDF]

Curr Oncol, 2022
Ball G, Lemieux C, Cameron D, Seftel MD.
europepmc   +1 more source

Arrhythmogenic Ventricular Remodeling by Next-Generation Bruton's Tyrosine Kinase Inhibitor Acalabrutinib. [PDF]

Int J Mol Sci
Zhao Y, Chakraborty P, Tomassetti J, Subha T, Massé S, Thavendiranathan P, Billia F, Lai PFH, Abdel-Qadir H, Nanthakumar K.   +9 more
europepmc   +1 more source

Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. [PDF]

Vet Dermatol, 2020
Goodale EC, White SD, Bizikova P, Borjesson D, Murrell DF, Bisconte A, Francesco M, Hill RJ, Masjedizadeh M, Nunn P, Gourlay SG, Jordan TJM, Emery CB, Outerbridge CA.   +13 more
europepmc   +1 more source